Integrated Bioelectronic HOBIT Device Sustains High-Density Implanted Cell Factories via Wireless In-Situ Water Splitting Oxygenation

Rice University's HOBIT implant generates its own oxygen to keep drug-producing cells alive. Discover how bioelectronics are revolutionizing cell therapy in 2026.

By: AXL Media

Published: Mar 28, 2026, 4:50 AM EDT

Source: Information for this report was sourced from Rice University

Engineering a Subcutaneous Bio-Factory

The challenge of implanting living cells to act as permanent drug dispensers has long been stymied by the hostile, low-oxygen environment beneath the human skin. While the subcutaneous space is ideal for minimally invasive surgery, it lacks the vascular density required to keep large numbers of engineered cells alive. According to the study published in Device, the Hybrid Oxygenation Bioelectronics system for Implanted Therapy, or HOBIT, overcomes this "oxygen desert" by integrating a miniature oxygen-making machine directly into the implant. This allows for a clinically meaningful dose of medication to be produced in a volume no larger than a folded stick of gum.

Electrocatalytic Oxygenation via Water Splitting

At the core of the HOBIT system is an advanced electrocatalytic oxygenator that utilizes an iridium oxide-based surface to generate life-sustaining gas. By using electricity from an on-board battery, the device splits water molecules found in the surrounding bodily tissue into oxygen without creating harmful chemical byproducts. This collaboration between energy research and bioengineering allows the device to function independently of the body's natural blood supply. According to Professor Tzahi Cohen-Karni of Carnegie Mellon, this localized generation ensures that even densely packed cell clusters receive the exact amount of oxygen required to maintain their metabolic functions.

Wireless Integration and High-Density Scaling

Earlier iterations of oxygen-generating implants were hampered by the need for external wiring, which increased the risk of infection and limited patient mobility. The current HOBIT platform represents a significant leap forward by fully integrating the oxygenator, battery, and control electronics into a wireless, self-contained unit. Professor Jonathan Rivnay of Northwestern University notes that this internal autonomy allowed the team to support cell densities roughly six times higher than conventional non-oxygenated methods. This increased density is crucial for keeping the device compact while still producing enough therapeutic material to treat chronic conditions.